Antibody molecules which bind cd45

Patent metadata

Field	Value
Publication number	US-2018237521-A1
Application number	US-201615743761-A
Country	US
Kind code	A1
Filing date	Jul 15, 2016
Priority date	Jul 16, 2015
Publication date	Aug 23, 2018
Grant date	—

Abstract

The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.

First claim

1 . An antibody molecule comprising a binding domain specific to CD45 comprising a heavy chain variable domain (VH) comprising:
CDRH1 of formula (I):

(SEQ ID NO: 1)

GX
1
SFSX
2
X
3
YX
4
X
5
X
6

wherein X 1 is F or V (such as F), X 2 is S, G or A (such as A), X 3 is G, S or N (such as G), X 4 is W or Y (such as W), X 5 is I or M (such as I), and X 6 is C, S or Y (such as S);
CDRH2 of formula (II):

(SEQ ID NO: 2)

X
7
X
8
YX
9
GX
10
SGSTYYAX
11
WX
12
X
13
X
14

wherein X 7 is C or S (such as S), X 8 is T, I or L (such as L or T, in particular L), X 9 is A or T (such as A), X 10 is R or S (such as R), X 11 is N or S (such as N), X 12 is V or A (such as A), X 13 is N or K (such as N), and X 14 is G, A, S or T (such as G),
CDRH3 has a formula

(SEQ ID NO: 3)

X
15
X
16
X
17
X
18
X
19
X
20
X
21
X
22
X
23
X
24
X
25
L

wherein X 15 is G, A, or D, X 16 is N, S or L, X 17 is A or G, X 18 is G, W or Y, X 19 is V, T or E, X 20 is I or absent, X 21 is D or absent, X 22 is G, S, A, T or Y, X 23 is Y, V or G, X 24 is G or M, and X 25 is G, A or D, and
a light chain variable domain (VL), wherein the light chain variable domain (VL) comprises:
a CDRL1 of formula (IV):

(SEQ ID NO: 4)

QASQSX
26
X
27
X
28
X
29
X
30
X
31
LX
32

wherein X 26 is I, F or V, X 27 is S or Y (such as Y), X 28 is N or S (such as N), X 29 is W, L or N (such as N), X 30 is N or absent, X 31 is N, S, Q or absent and X 32 is S or A;
a CDRL2 of formula (V):

(SEQ ID NO: 5)

X
33
ASX
34
LAS

wherein X 33 is Q, G or D, and X 34 is K, N or D;
a CDRL3 of formula (VI):

(SEQ ID NO: 6)

X
35
X
36
X
37
X
38
X
39
X
40
X
41
SX
42
X
43
X
44
X
45
X
46

wherein X 35 is Q or absent, X 36 is S or L (such as L), X 37 is Y, A or G, X 38 is Y, G or absent (such as Y), X 39 is D or Y (such as D), X 40 is G, A, T, S or Y, X 41 is G or S, X 42 is N, S, Y or G, X 43 is V, A or W, X 44 is F or Y or absent, X 45 is F or absent and X 46 is N, A or absent.

2 . (canceled)

3 . An antibody molecule according to claim 1 , wherein CDRH1 is formula (Ia):

(SEQ ID NO: 7)

GFSFSX 2 X 3 YX 4 X 5 X 6 [[.]]

or

(SEQ ID NO: 8)

GFSFSX 2 X 3 YWIX 6 ,

wherein X 2 , X 3 , X 4 , X 5 and X 6 are defined above for formula (I).

4 . (canceled)

5 . An antibody molecule according to claim 1 , wherein
a. CDR H1 is SEQ ID NO: 1, 7 or 8 and CDR H2 is SEQ ID NO: 2, or CDR H1 is SEQ ID NO: 1, 7 or 8 and CDR H3 is SEQ ID NO: 3, or CDR H2 is SEQ ID NO: 2 and CDR H3 is SEQ ID NO: 3 or b. CDRH1 is independently selected from SEQ ID NO: 10, 11, 12, 13, 14, 15 and 16, CDR

Assignees

• Ucb Biopharma Sprl

Inventors

• Finney Helene Margaret
• Rapecki Stephen Edward
• Tyson Kerry Louise
• Wright Michael John

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K16/18

  against material from animals or humans · CPC title